{"id":"intravenous-rhtnk-tpa","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (intracranial and systemic)"},{"rate":null,"effect":"Reperfusion arrhythmias"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is a genetically engineered tissue plasminogen activator (tPA) variant designed to improve thrombolytic efficacy and safety in acute thrombotic conditions. By enhancing fibrin specificity and reducing systemic plasminogen activation compared to conventional tPA, it aims to achieve faster clot dissolution with potentially lower bleeding risk. The recombinant human TNK-tPA (tenecteplase-like variant) is administered intravenously for rapid thrombus resolution.","oneSentence":"rhTNK-tPA is a recombinant thrombolytic agent that dissolves blood clots by converting plasminogen to plasmin, enabling fibrin degradation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:53.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Acute myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07203625","phase":"PHASE4","title":"Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-20","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":316},{"nctId":"NCT05701956","phase":"PHASE3","title":"Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion","status":"COMPLETED","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2023-03-16","conditions":"Basilar Artery Occlusion, Acute Cerebrovascular Accident, Stroke Due to Basilar Artery Occlusion","enrollment":330},{"nctId":"NCT06987305","phase":"PHASE3","title":"Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window","status":"RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2025-10-21","conditions":"Stroke, Acute Ischemic","enrollment":820},{"nctId":"NCT07201688","phase":"PHASE3","title":"Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.","status":"RECRUITING","sponsor":"CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-30","conditions":"Acute Ischemic Stroke","enrollment":890},{"nctId":"NCT05752916","phase":"PHASE4","title":"Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-06-02","conditions":"Acute Ischemic Stroke","enrollment":570},{"nctId":"NCT06196320","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-01-24","conditions":"Ischemic Stroke, Acute","enrollment":452},{"nctId":"NCT06414499","phase":"PHASE3","title":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-09","conditions":"Minor Ischemic Stroke","enrollment":1386},{"nctId":"NCT04733742","phase":"PHASE2, PHASE3","title":"Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2022-05-09","conditions":"Stroke, Acute, Stroke, Ischemic","enrollment":550},{"nctId":"NCT04588337","phase":"","title":"INtravenous TNK for Acute isChemicsTroke in China","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2022-01-06","conditions":"Stroke, Ischemic","enrollment":1000},{"nctId":"NCT06078995","phase":"","title":"Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2023-04-02","conditions":"Ischemic Stroke","enrollment":1200},{"nctId":"NCT04797013","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2021-06-12","conditions":"Acute Ischemic Stroke","enrollment":1430}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intravenous tenecteplase","Intravenous TNK"],"phase":"phase_3","status":"active","brandName":"Intravenous rhTNK-tPA","genericName":"Intravenous rhTNK-tPA","companyName":"Xinqiao Hospital of Chongqing","companyId":"xinqiao-hospital-of-chongqing","modality":"Small molecule","firstApprovalDate":"","aiSummary":"rhTNK-tPA is a recombinant thrombolytic agent that dissolves blood clots by converting plasminogen to plasmin, enabling fibrin degradation. Used for Acute ischemic stroke, Acute myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}